

United States Preventative Services Task Force (USPSTF) Recommendation or Institutes of Medicine Women's Preventive Recommendations	key word	Recommended age	USPSTF grade	CPT/HCPCS or Therapeutic Class Code (check for code validity based on service date)*	ICD-10	Reasonable Medical Management - limits applied. (If blank, limit was specified by USPSTF)
The USPSTF recommends 1-time screening for abdominal aortic aneurysm (AAA) with ultrasonog- raphy in men aged 65 to 75 years who have ever smoked.	AAA	65-75	В	76706	F17.200, F17.201, F17.203, F17.208, F17.209, F17.210, F17.211, F17.213, F17.218, F17.219, F17.220, F17.221, F17.223, F17.228, F17.229, F17.290, F17. 291, F17.293, F17.298, F17.299, Z87.891	
The USPSTF recommends that clinicians screen adults aged 18 years or older for alcohol misuse and provide persons engaged in risky or hazardous drinking with brief behavioral counseling interventions to reduce alcohol misuse.	alcohol		В	99408, 99409	Z71.41	
"The USPSTF recommends the application of fluoride varnish to the primary teeth of all infants and children starting at the age of primary tooth eruption in primary care practices. The USPSTF recommends prima- ry care clinicians prescribe oral fluoride supplementation start- ing at age 6 months for children whose water supply is fluoride deficient. See Prev Meds Tab (formerly OTC Drugs)"	fluoride	6 months up to age 5 years	В	99381, 99382, 99391, 99392		See other row(s) with keyword fluoride



United States Preventative Services Task Force (USPSTF) Recommendation or Institutes of Medicine Women's Preventive Recommendations	key word	Recommended age	USPSTF grade	CPT/HCPCS or Therapeutic Class Code (check for code validity based on service date)*	ICD-10	Reasonable Medical Management - limits applied. (If blank, limit was specified by USPSTF)
The USPSTF recommends screening for major depressive disorder (MDD) in adolescents aged 12 to 18 years.	Depression Screening: adolescents	12-18	В	96127*, 99384, 99385, 99394, 99395		
"The USPSTF recommends screening for depression in the adult population, including preg- nant and postpartum persons, as well as older adults. "	Depression Screening	18 years and older	В	99385, 99386, 99387, 99395, 99396, 99397		
The USPSTF recommends screening for anxiety in children and adolescents aged 8 to 18 years.	anxiety	8-18	В	99383, 99384, 99385, 99393, 99394, 99395		
The USPSTF recommends screening for anxiety disorders in adults, including pregnant and postpartum persons.	anxiety		В	99385, 99386, 99387, 99395, 99396, 99397		
The USPSTF recommends screening for hypertension in adults 18 years or older with office blood pressure measurement (OBPM). The USPSTF recom- mends obtaining blood pressure measurements outside of the clin- ical setting for diagnostic confir- mation before starting treatment.	"hyperten- sion screen- ing, blood pressure "		A	99385, 99386, 99387, 99395, 99396, 99397		



United States Preventative Services Task Force (USPSTF) Recommendation or Institutes of Medicine Women's Preventive Recommendations	key word	Recommended age	USPSTF grade	CPT/HCPCS or Therapeutic Class Code (check for code validity based on service date)*	ICD-10	Reasonable Medical Management - limits applied. (If blank, limit was specified by USPSTF)
The USPSTF recommends that primary care clinicians provide interventions, including education or brief counseling, to prevent initiation of tobacco use among school-aged children and adoles- cents.	tobacco	17 years and younger	В	99383, 99384, 99393, 99394		
"The USPSTF strongly recom- mends that clinicians screen all adults for tobacco use and pro- vide tobacco cessation interven- tions for those who use tobacco products. The USPSTF strongly recom- mends that clinicians screen all pregnant women for tobacco use and provide augmented pregnan- cy-tailored counseling to those who smoke. See Prev Meds Tab (formerly OTC Drugs)"	tobacco screening		A	99385, 99386, 99387, 99395 99396, 99397		



United States Preventative Services Task Force (USPSTF) Recommendation or Institutes of Medicine Women's Preventive Recommendations	key word	Recommended age	USPSTF grade	CPT/HCPCS or Therapeutic Class Code (check for code validity based on service date)*	ICD-10	Reasonable Medical Management - limits applied. (If blank, limit was specified by USPSTF)
The USPSTF recommends screening by asking questions about unhealthy drug use in adults age 18 years or older. Screening should be implemented when services for accurate diag- nosis, effective treatment, and appropriate care can be offered or referred. (Screening refers to asking questions about unhealthy drug use, not testing biological specimens.)	drug	18 years and older	В	99385, 99386, 99387, 99395 99396, 99397		
Bright Futures (a set of recom- mendations made by the Amer- ican Academy of Pediatrics. https://downloads.aap.org/AAP/ PDF/periodicity_schedule.pdf	Bright Fu- tures	0-21		96127*, 99381, 99382, 99383, 99384, 99385, 99391, 99392, 99393, 99394, 99395		
"The USPSTF recommends screening to detect amblyopia, strabismus, and defects in visual acuity in children younger than age 5 years	visual acuity	<5	В	99381, 99382, 99383, 99391, 99392, 99393		



United States Preventative Services Task Force (USPSTF) Recommendation or Institutes of Medicine Women's Preventive Recommendations	key word	Recommended age	USPSTF grade	CPT/HCPCS or Therapeutic Class Code (check for code validity based on service date)*	ICD-10	Reasonable Medical Management - limits applied. (If blank, limit was specified by USPSTF)
The USPSTF recommends coun- seling young adults, adolescents, children, and parents of young children about minimizing expo- sure to ultraviolet (UV) radiation for persons aged 6 months to 24 years with fair skin types to reduce their risk of skin cancer.	skin cancer behavioral counseling	6 months up to 24 years	В	99381, 99382, 99383, 99384, 99385, 99391, 99392, 99393, 99394, 99395		
The USPSTF recommends exer- cise interventions to prevent falls in community-dwelling adults 65 years or older who are at in- creased risk for falls.	Falls pre- vention: older adults	65 years and older	В	99387, 99397		
Counseling for Sexually Transmit- ted Infections, HIV, Contraception and interpersonal and domestic violence	Domestic violence and STI			99381, 99382, 99383, 99391, 99392, 99393		
The USPSTF recommends be- havioral counseling for all sexually active adolescents and for adults at increased risk for sexually transmitted infections (STIs)	STI	adolescents to adults	В	99401, 99402, 99403, 99404, 99411, 99412	Z71.89	decision made to allow 3 hours
The USPSTF recommends screening to detect amblyopia, strabismus, and defects in visual acuity in children younger than age 5 years	vision screen by optometry, visual acuity	<5	В	92002, 92004, 92012, 92014, S0620, S0621	Z01.00, Z01.01	



United States Preventative Services Task Force (USPSTF) Recommendation or Institutes of Medicine Women's Preventive Recommendations	key word	Recommended age	USPSTF grade	CPT/HCPCS or Therapeutic Class Code (check for code validity based on service date)*	ICD-10	Reasonable Medical Management - limits applied. (If blank, limit was specified by USPSTF)
"The USPSTF strongly recom- mends that clinicians screen all adults for tobacco use and pro- vide tobacco cessation interven- tions for those who use tobacco products. The USPSTF strongly recom- mends that clinicians screen all pregnant women for tobacco use and provide augmented pregnan- cy-tailored counseling to those who smoke. See Prev Meds Tab (formerly OTC Drugs)"	tobacco screening, tobacco intervention		A	99406, 99407, 99411, 99412	F17.200, F17.201, F17.210, F17.211, F17.220, F17.221, F17.290, F17.291, F17.203, F17.208, F17.209, F17.213, F17.218, F17.219, F17.223, F17.228, F17.229, F17.293, F17.298, F17.299	



United States Preventative Services Task Force (USPSTF) Recommendation or Institutes of Medicine Women's Preventive Recommendations	key word	Recommended age	USPSTF grade	CPT/HCPCS or Therapeutic Class Code (check for code validity based on service date)*	ICD-10	Reasonable Medical Management - limits applied. (If blank, limit was specified by USPSTF)
The USPSTF recommends screening pregnant persons for asymptomatic bacteriuria using urine culture.	bacteriuria		В	87086, 87081, 87084	009.00, 009.01, 009.02,   009.03, 009.10, 009.11,   009.12, 009.13, 009.211,   009.212, 009.213, 090.219,   009.291, 009.292, 009.293,   009.299, 009.30, 009.31,   009.32, 009.33, 009.40,   009.41, 009.42, 009.43,   009.511, 009.512, 009.513,   009.523, 009.529, 009.611,   009.621, 009.622, 009.623,   009.621, 009.622, 009.623,   009.629, 009.70, 009.71,   009.72, 009.73, 009.811,   009.821, 009.822, 009.823,   009.829, 009.891, 009.892,   009.829, 009.891, 009.892,   009.83, 009.899, 009.90,   009.41, 009.41, 009A2,   009.43, Z33.1, Z33.3, Z34.00,   Z34.80, Z34.81, Z34.82,   Z34.83, Z34.90, Z34.91,   Z34.92, Z34.93	



United States Preventative Services Task Force (USPSTF) Recommendation or Institutes of Medicine Women's Preventive Recommendations	key word	Recommended age	USPSTF grade	CPT/HCPCS or Therapeutic Class Code (check for code validity based on service date)*	ICD-10	Reasonable Medical Management - limits applied. (If blank, limit was specified by USPSTF)
USPSTF recommends that prima- ry care clinicians assess women with a personal or family history of breast, ovarian, tubal, or perito- neal cancer or who have an ances- try associated with breast cancer susceptibility 1 and 2 (BRCA1/2) gene mutations with an appro- priate brief familial risk assess- ment tool. Women with a positive result on the risk assessment tool should receive genetic counseling and, if indicated after counseling, genetic testing.	BRCA		В	99401, 99402, 99403, 99404, 81162, 81163, 81164, 81165, 81166, 81167, 81212, 81215, 81216, 81217, 81406	Z80.3, Z80.41, Z85.3, Z85.43	Medical Policy in place for BRCA1 and BRCA2 codes, see web
Breast Cancer Screening	Breast/ mammo- gram		В,	77063, 77067	Z80.3, Z12.39, Z12.31	
USPSTF recommends interven- tions during pregnancy and after birth to promote and support breastfeeding	breastfeed- ing		В	99211, S9443	Z39.1	
Breast Pumps	Breast pump			E0602, E0603, A4281, A4282, A4283, A4284, A4285, A4286, A4287		



United States Preventative Services Task Force (USPSTF) Recommendation or Institutes of Medicine Women's Preventive Recommendations	key word	Recommended age	USPSTF grade	CPT/HCPCS or Therapeutic Class Code (check for code validity based on service date)*	ICD-10	Reasonable Medical Management - limits applied. (If blank, limit was specified by USPSTF)
"The USPSTF recommends screening for cervical cancer every 3 years with cervical cytolo- gy alone in women aged 21 to 29 years. For women aged 30 to 65 years, the USPSTF recommends screening every 3 years with cervical cytolo- gy alone, every 5 years with high-risk human papillomavirus (hrHPV) testing alone, or every 5 years with hrHPV test- ing in combination with cytology (cotesting)."	Cervical / pap	"21 - 29 years 30 - 65 years"	A	88141, 88142, 88143, 88147, 88148, 88150, 88152, 88153, 88155, 88164, 88165, 88166, 88167, 88174, 88175, G0123, G0124, G0141, G0143, G0144, G0145, G0147, G0148, P3000, P3001, Q0091	Z00.00, Z00.01, Z00.8, Z01.411, Z01.419, Z12.4, Z87.410	



United States Preventative Services Task Force (USPSTF) Recommendation or Institutes of Medicine Women's Preventive Recommendations	key word	Recommended age	USPSTF grade	CPT/HCPCS or Therapeutic Class Code (check for code validity based on service date)*	ICD-10	Reasonable Medical Management - limits applied. (If blank, limit was specified by USPSTF)
"The USPSTF recommends screening for cervical cancer every 3 years with cervical cytolo- gy alone in women aged 21 to 29 years. For women aged 30 to 65 years, the USPSTF recommends screening every 3 years with cervical cytolo- gy alone, every 5 years with high-risk human papillomavirus (hrHPV) testing alone, or every 5 years with hrHPV test- ing in combination with cytology (cotesting)."	HPV	30 - 65 years		87623, 87624, 87625	Z11.51	
USPSTF recommends screening for chlamydia in all sexually active women 24 years or younger and in women 25 years or older who are at increased risk for infection.	chlamydia		В	86631, 86632, 87110, 87270, 87490, 87491, 87810	Z11.3, Z11.8, Z20.2, Z72.51, Z72.52, Z72.53	



United States Preventative Services Task Force (USPSTF) Recommendation or Institutes of Medicine Women's Preventive Recommendations	key word	Recommended age	USPSTF grade	CPT/HCPCS or Therapeutic Class Code (check for code validity based on service date)*	ICD-10	Reasonable Medical Management - limits applied. (If blank, limit was specified by USPSTF)
"USPSTF recommends screening for colorectal cancer in all adults aged 50 to 75 years. The USPSTF recommends screening for colorectal cancer in adults aged 45 to 49 years. See Prev Meds Tab (formerly OTC Drugs)"	"colorectal screening, colon, colo- noscopy, bowel prep"	"50 - 75 (includ- ing age 75) 45-49 "	"A "	"00812, 44389, 44390, 44391, 44392, 44394, 44401, 45330, 45331, 45333, 45334, 45338, 45346, 45378, 45379, 45380, 45381, 45382, 45384, 45385, 45386, 45388, 45389, 45390, 45391, 45392, 81528, 82270, 82274, 88305, 99152, 99153, 99156, 99157, G0104, G0105, G0121, G0328, S0285 •Rev code 00370 (when billed without a HCPCS proc cd), •Rev code 00710 (when billed without a HCPCS proc cd),	Z12.11, Z12.12	
USPSTF recommends screening for congenital hypothyroidism (CH) in newborns	hypothyroid- ism	Under age 1 year	A	84436, 84437, 84439, 84443	Z13.29	



United States Preventative Services Task Force (USPSTF) Recommendation or Institutes of Medicine Women's Preventive Recommendations	key word	Recommended age	USPSTF grade	CPT/HCPCS or Therapeutic Class Code (check for code validity based on service date)*	ICD-10	Reasonable Medical Management - limits applied. (If blank, limit was specified by USPSTF)
"The USPSTF recommends offer- ing or referring adults with cardi- ovascular disease risk factors to behavioral counseling interven- tions to promote a healthy diet and physical activity.	hyperlipi- demia, car- diovascular		В	97802, 97803, 97804	E66.01, E66.09, E66.1, E66.2, E66.8, E66.9, Z68.30, Z68.31, Z68.32, Z68.33, Z68.34, Z68.35, Z68.36, Z68.37, Z68.38, Z68.39, Z68.41, Z68.42, Z68.43, Z68.44, Z68.45, Z71.3	7 hours total
The USPSTF recommends that clinicians screen all adult patients for obesity and offer intensive counseling and behavioral inter- ventions to promote sustained weight loss for obese adults.	obesity		В	97802, 97803, 97804	E66.01, E66.09, E66.1, E66.2, E66.8, E66.9, Z68.30, Z68.31, Z68.32, Z68.33, Z68.34, Z68.35, Z68.36, Z68.37, Z68.38, Z68.39, Z68.41, Z68.42, Z68.43, Z68.44, Z68.45, Z71.3	
The USPSTF recommends that clincians provide or refer pregnant and postpartum persons who are at increased risk of perinatal depression to counseling inter- ventions	pregnant and po- spartum persons, perinatal depression		В	99401, 99402, 99403, 99404, 99411, 99412		
USPSTF recommends screening for gonorrhea in all sexually active women 24 yars or younger and in women 25 years or older who are at increased risk for infection.	gonorrhea		В	87590, 87591, 87850	Z11.3, Z11.8, Z20.2, Z72.51, Z72.52, Z72.53	



United States Preventative Services Task Force (USPSTF) Recommendation or Institutes of Medicine Women's Preventive Recommendations	key word	Recommended age	USPSTF grade	CPT/HCPCS or Therapeutic Class Code (check for code validity based on service date)*	ICD-10	Reasonable Medical Management - limits applied. (If blank, limit was specified by USPSTF)
The USPSTF recommends prophylactic ocular topical medi- cation for all newborns to prevent gonococcal ophthalmia neonato- rum.	gonococcal ophthalmia neonatorum		A	GPI 86101025004210		
USPSTF recommends screening for hearing loss in all newborn infants.	hearing		В	92587, 92588	Z00.121, Z00.129, Z01.10, Z01.118	



United States Preventative Services Task Force (USPSTF) Recommendation or Institutes of Medicine Women's Preventive Recommendations	key word	Recommended age	USPSTF grade	CPT/HCPCS or Therapeutic Class Code (check for code validity based on service date)*	ICD-10	Reasonable Medical Management - limits applied. (If blank, limit was specified by USPSTF)
"The USPSTF recommends that clinicians screen for HIV infection in adolescents and adults ages 15 to 65 years. Younger adoles- cents and older adults who are at increased risk should also be screened. The USPSTF recommends that clinicians screen for HIV infection in all pregnant persons, including those who present in labor or at delivery whose HIV status is unknown. "	HIV	adolescent to adult	A	80081, 86701, 86702, 86703, 87389, 87390, 87391, G0432, G0433, G0435	009.00, 009.01, 009.02,   009.03, 009.10, 009.11,   009.12, 009.13, 009.211,   009.212, 009.213, 009.219,   009.291, 009.292, 009.293,   009.299, 009.30, 009.31,   009.32, 009.33, 009.40,   009.41, 009.42, 009.43,   009.511, 009.512, 009.513,   009.519, 009.521, 009.522,   009.621, 009.613, 009.619,   009.621, 009.622, 009.623,   009.629, 009.70, 009.71,   009.72, 009.73, 009.811,   009.821, 009.822, 009.823,   009.821, 009.822, 009.823,   009.829, 009.891, 009.892,   009.83, 009.899, 009.90,   009.91, 009.92, 009.93,   009.41, 234.03, Z34.80,   Z34.81, Z34.82, Z34.83,   Z34.90, Z34.91, Z34.92,   Z34.93, Z71.7	



United States Preventative Services Task Force (USPSTF) Recommendation or Institutes of Medicine Women's Preventive Recommendations	key word	Recommended age	USPSTF grade	CPT/HCPCS or Therapeutic Class Code (check for code validity based on service date)*	ICD-10	Reasonable Medical Management - limits applied. (If blank, limit was specified by USPSTF)
"The USPSTF recommends that clinicians prescribe preexposure prophylaxis (PrEP) using effective antiretroviral therapy to persons who are at increased risk of HIV acquisition to decrease the risk of acquiring HIV. •See Prev Meds Tab (formerly OTC Drugs) •See ACA Prevention Copay Waiver Criteria (on myprime.com or bcbsks.com medical policy page)"	HIV PrEP (preexpo- sure proph- ylaxis)		A	"Preventive Code PREP on stand- alone drug inquiry. Kidney Function Testing: 82565 HIV Testing: 80081, 86701, 86702, 86703, 87389, 87390, 87391, G0432, G0433, G0435	Z11.4, Z20.6, Z71.7	



United States Preventative Services Task Force (USPSTF) Recommendation or Institutes of Medicine Women's Preventive Recommendations	key word	Recommended age	USPSTF grade	CPT/HCPCS or Therapeutic Class Code (check for code validity based on service date)*	ICD-10	Reasonable Medical Management - limits applied. (If blank, limit was specified by USPSTF)
USPSTF recommends routine screening for iron deficiency anemia in asymptomatic pregnant women	iron de- ficiency anemia		В	80055, 80081	O09.00, O09.01, O09.02, O09.03, O09.10, O09.11, O09.12, O09.13, O09.211, O09.291, O09.292, O09.293, O09.299, O09.30, O09.31, O09.299, O09.30, O09.31, O09.32, O09.33, O09.40, O09.41, O09.42, O09.43, O09.511, O09.521, O09.522, O09.523, O09.529, O09.611, O09.621, O09.622, O09.623, O09.629, O09.70, O09.71, O09.812, O09.813, O09.811, O09.821, O09.822, O09.823, O09.893, O09.891, O09.823, O09.891, O09.891, O09.893, O09.90, O09.91, O09.92, O09.93, O09.00, A1, C09. A2, O09.A3, Z33.1, Z33.3, Z34.00, Z34.01, Z34.90, Z34.91, Z34.92, Z34.93	Allow 1 OB panel 80055 or 1- 80081 for rows with key- words iron deficiency anemia, hepatitis B (pregnant), Rh and pregnant syphilis per benefit period.



United States Preventative Services Task Force (USPSTF) Recommendation or Institutes of Medicine Women's Preventive Recommendations	key word	Recommended age	USPSTF grade	CPT/HCPCS or Therapeutic Class Code (check for code validity based on service date)*	ICD-10	Reasonable Medical Management - limits applied. (If blank, limit was specified by USPSTF)
U.S. Preventive Services Task Force (USPSTF) strongly recom- mends screening for hepatitis B virus (HBV) infection in pregnant women at their first prenatal visit.	hepatitis B (pregnant)		A	80055, 80081	009.00, 009.01, 009.02, 009.03, 009.10, 009.11, 009.12, 009.13, 009.211, 009.212, 009.213, 009.219, 009.291, 009.292, 009.293, 009.299, 009.30, 009.31, 009.32, 009.33, 009.40, 009.41, 009.42, 009.43, 009.511, 009.512, 009.522, 009.523, 009.529, 009.611, 009.621, 009.622, 009.623, 009.629, 009.70, 009.71, 009.72, 009.73, 009.811, 009.821, 009.822, 009.823, 009.829, 009.891, 009.822, 009.893, 009.891, 009.892, 009.893, 009.899, 009.90, 009.91, 009.92, 009.93, 009.41, 234.01, Z34.82, Z34.83, Z34.90, Z34.91, Z34.92, Z34.93	Allow 1 OB panel 80055 or 1- 80081 for rows with key- words iron deficiency anemia, hepatitis B (pregnant), Rh and pregnant syphilis per benefit period.



United States Preventative Services Task Force (USPSTF) Recommendation or Institutes of Medicine Women's Preventive Recommendations	key word	Recommended age	USPSTF grade	CPT/HCPCS or Therapeutic Class Code (check for code validity based on service date)*	ICD-10	Reasonable Medical Management - limits applied. (If blank, limit was specified by USPSTF)
The U.S. Preventive Services Task Force (USPSTF) strongly recommends Rh (D) blood typing and antibody testing for all preg- nant women during their first visit for pregnancy-related care	Rh		A	80055, 80081	009.00, 009.01, 009.02,   009.03, 009.10, 009.11,   009.12, 009.13, 009.211,   009.212, 009.213, 009.219,   009.291, 009.292, 009.293,   009.299, 009.30, 009.31,   009.32, 009.33, 009.40,   009.41, 009.42, 009.43,   009.511, 009.512, 009.513,   009.523, 009.529, 009.611,   009.621, 009.622, 009.623,   009.621, 009.622, 009.623,   009.629, 009.70, 009.71,   009.72, 009.73, 009.811,   009.821, 009.822, 009.823,   009.829, 009.891, 009.892,   009.829, 009.891, 009.892,   009.829, 009.813, 009.819,   009.821, 009.822, 009.833,   009.829, 009.891, 009.892,   009.803, 009.809, 009.90,   009.41, 009.41, 009.   A2, 009.A3, Z33.1, Z33.3,   Z34.00, Z34.01, Z34.02,   Z34.03, Z34.80, Z34.81,   Z34.91, Z34.92, Z34.93	Allow 1 OB panel 80055 or 1- 80081 for rows with key- words iron deficiency anemia, hepatitis B (pregnant), Rh and pregnant syphilis per benefit period.



United States Preventative Services Task Force (USPSTF) Recommendation or Institutes of Medicine Women's Preventive Recommendations	key word	Recommended age	USPSTF grade	CPT/HCPCS or Therapeutic Class Code (check for code validity based on service date)*	ICD-10	Reasonable Medical Management - limits applied. (If blank, limit was specified by USPSTF)
The USPSTF recommends early screening for syphilis infection in all pregnant women.	pregnant syphilis		A	80055, 80081	009.00, 009.01, 009.02,   009.03, 009.10, 009.11,   009.12, 009.13, 009.211,   009.212, 009.213, 009.219,   009.291, 009.292, 009.293,   009.299, 009.30, 009.31,   009.32, 009.33, 009.40,   009.41, 009.42, 009.43,   009.511, 009.512, 009.513,   009.519, 009.521, 009.522,   009.623, 009.529, 009.611,   009.621, 009.613, 009.619,   009.629, 009.70, 009.71,   009.72, 009.73, 009.811,   009.812, 009.813, 009.819,   009.821, 009.822, 009.823,   009.821, 009.813, 009.819,   009.821, 009.813, 009.819,   009.821, 009.813, 009.813,   009.823, 009.899, 009.90,   009.91, 009.92, 009.93,   009.41, 009.41, 009.   A2, 009.A3, Z33.1, Z33.3,   Z34.03, Z34.80, Z34.81,   Z34.03, Z34.83, Z34.90,   Z34.91, Z34.92, Z34.93	Allow 1 OB panel 80055 or 1- 80081 for rows with key- words iron deficiency anemia, hepatitis B (pregnant), Rh and pregnant syphilis per benefit period.
The USPSTF recommends screening for syphilis infection in persons who are at increased risk for infection.	syphilis		A	86592, 86780	Z11.3, Z11.8, Z20.2, Z72.51, Z72.52, Z72.53	



United States Preventative Services Task Force (USPSTF) Recommendation or Institutes of Medicine Women's Preventive Recommendations	key word	Recommended age	USPSTF grade	CPT/HCPCS or Therapeutic Class Code (check for code validity based on service date)*	ICD-10	Reasonable Medical Management - limits applied. (If blank, limit was specified by USPSTF)
The U.S. Preventive Services Task Force (USPSTF) strongly recommends screening men aged 35 and older for lipid disorders	lipid	OVER 35	A	80061, 82465, 83718	Z13.220	1/yr
The USPSTF recommends screening men aged 20 to 35 for lipid disorders if they are at increased risk for coronary heart disease	lipid	20-35	В	80061, 82465, 83718	Z13.220	1/yr
The USPSTF strongly recom- mends screening women aged 45 and older for lipid disorders if they are at increased risk for coronary heart disease.	lipid	over 45	A	80061, 82465, 83718	Z13.220	1/yr
The USPSTF recommends screening women aged 20 to 45 for lipid disorders if they are at increased risk for coronary heart disease	lipid	20-45	В	80061, 82465, 83718	Z13.220	1/yr



United States Preventative Services Task Force (USPSTF) Recommendation or Institutes of Medicine Women's Preventive Recommendations	key word	Recommended age	USPSTF grade	CPT/HCPCS or Therapeutic Class Code (check for code validity based on service date)*	ICD-10	Reasonable Medical Management - limits applied. (If blank, limit was specified by USPSTF)
"The USPSTF recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in postmenopausal women younger than 65 years who are at in- creased risk of osteoporosis, as determined by a formal clinical risk assessment tool. The USPSTF recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in women 65 years and older."	osteoporo- sis	"< 65 ≥ 65"	В	77080, 77085	Z13.820	
The USPSTF recommends screening for phenylketonuria (PKU) in newborns	PKU	newborn	A	84030	Z13.228	



United States Preventative Services Task Force (USPSTF) Recommendation or Institutes of Medicine Women's Preventive Recommendations	key word	Recommended age	USPSTF grade	CPT/HCPCS or Therapeutic Class Code (check for code validity based on service date)*	ICD-10	Reasonable Medical Management - limits applied. (If blank, limit was specified by USPSTF)
The USPSTF recommends repeated Rh (D) antibody testing for all unsensitized Rh (D)-negative women at 24-28 weeks' gestation, unless the biological father is known to be Rh (D)-negative.	Rh		В	86850	O09.00, O09.01, O09.02, O09.03, O09.10, O09.11, O09.12, O09.13, O09.211, O09.212, O09.213, O90.219, O09.291, O09.292, O09.293, O09.299, O09.30, O09.31, O09.32, O09.33, O09.40, O09.41, O09.42, O09.43, O09.511, O09.521, O09.513, O09.519, O09.521, O09.522, O09.523, O09.529, O09.611, O09.612, O09.613, O09.619, O09.621, O09.622, O09.623, O09.629, O09.70, O09.71, O09.72, O09.73, O09.811, O09.812, O09.813, O09.819, O09.821, O09.822, O09.823, O09.829, O09.891, O09.892, O09.893, O09.891, O09.892, O09.91, O09.92, O09.93, O09.A0, O09A1, O09A2, O09A3, Z33.1, Z33.3, Z34.00, Z34.01, Z34.02, Z34.03, Z34.80, Z34.81, Z34.82, Z34.83, Z34.90, Z34.91, Z34.92, Z34.93	



United States Preventative Services Task Force (USPSTF) Recommendation or Institutes of Medicine Women's Preventive Recommendations	key word	Recommended age	USPSTF grade	CPT/HCPCS or Therapeutic Class Code (check for code validity based on service date)*	ICD-10	Reasonable Medical Management - limits applied. (If blank, limit was specified by USPSTF)
The USPSTF recommends high-intensity behavioral coun- seling to prevent sexually trans- mitted infections (STIs) for all sexually active adolescents and for adults at increased risk for STIs.	STI	adolescents to adults	В	99401, 99402, 99403, 99404	Z71.89	decision made to allow 3 hours
The U. S. Preventive Services Task Force (USPSTF) recom- mends screening for sickle cell disease in newborns	sickle	newborn	A	83020, 83021	Z13.0	
The USPSTF recommends screening for prediabetes and type 2 diabetes in adults aged 35 to 70 years who have overweight or obesity. Clinicians should offer or refer patients with prediabetes to effective preventive interven- tions.	diabetes, prediabetes		В	82947, 82950, 83036	Z13.1	
"The USPSTF recommends that clinicians discuss chemopreven- tion with women at high risk for breast cancer and at low risk for adverse effects of chemopre- vention. Clinicians should inform patients of the potential benefits and harms of chemoprevention. See Prev Meds Tab (formerly OTC Drugs)"	chemopre- vention		В	"99401, 99402 Tamoxifen generics, Evista(raloxifene) as prescribed for prevention see NDC tab as necessary"	Z80.3	



United States Preventative Services Task Force (USPSTF) Recommendation or Institutes of Medicine Women's Preventive Recommendations	key word	Recommended age	USPSTF grade	CPT/HCPCS or Therapeutic Class Code (check for code validity based on service date)*	ICD-10	Reasonable Medical Management - limits applied. (If blank, limit was specified by USPSTF)
The USPSTF recommends that clinicians screen children aged 6 years and older for obesity and offer them or refer them to com- prehensive, intensive behavioral interventions to promote improve- ment in weight status.	obesity	6	В	97802, 97803, 97804	Z68.54	
Bright Futures and the American Academy of Pediatrics recom- mendations include screening tests for hematocrit or hemoglo- bin as necessary based on risk assessment at age 12 months. *Bright Futures recommendations are a part of the Health Care Resources Administration (HRSA) recommendations.	H&H	12 months		85014, 85018 or 85027	Z13.0	
Bright Futures and the American Academy of Pediatrics recom- mendations include screening tests for lead exposure as neces- sary based on risk assessment at age 12 months and possibly again at 24 months. *Bright Fu- tures recommendations are a part of the Health Care Resources Administration (HRSA) recom- mendations.	Lead	12 and 24 months		83655	Z77.011	



United States Preventative Services Task Force (USPSTF) Recommendation or Institutes of Medicine Women's Preventive Recommendations	key word	Recommended age	USPSTF grade	CPT/HCPCS or Therapeutic Class Code (check for code validity based on service date)*	ICD-10	Reasonable Medical Management - limits applied. (If blank, limit was specified by USPSTF)
"The U.S. Preventive Services Task Force (USPSTF) recom- mends routine iron supplemen- tation for asymptomatic children aged 6 to 12 months who are at increased risk for iron deficiency anemia See Prev Meds Tab (formerly OTC Drugs)"	iron	6-12 months	В	OTC iron supp		
"The USPSTF recommends that all persons planning to or who could become pregnant take a daily supplement containing 0.4 to 0.8 mg (400 to 800 mcg) of folic acid. See Prev Meds Tab (formerly OTC Drugs)"	folic acid		A			
Uniform Screening Panel	panel					
HRSA Women Recommendations * CPT/HCPCS codes are only valid as recommendation if the code itself is effective at the date of service.						
"Contraception(non-oral) See Prev Meds Tab (formerly OTC Drugs)"	Hormone releasing vaginal ring(Nuvar- ing)			G9B, J7295	Z30.013, Z30.014, Z30.015, Z30.018, Z30.019, Z30.40, Z3044	



United States Preventative Services Task Force (USPSTF) Recommendation or Institutes of Medicine Women's Preventive Recommendations	key word	Recommended age	USPSTF grade	CPT/HCPCS or Therapeutic Class Code (check for code validity based on service date)*	ICD-10	Reasonable Medical Management - limits applied. (If blank, limit was specified by USPSTF)
	Intrauter- ine Device (IUD)			58300, 58301, J7296, J7297, J7298, J7300, J7301, S4981, S4989, Q0090, X1C	Z30.014, Z30.018, Z30.019, Z30.40, Z30.430, Z30.431, Z30.432, Z30.433, Z30.49	
	Implantable systems			11976, 11981, 11982, 11983, J7306, J7307, G8B	Z30.017, Z30.40, Z30.46, Z30.49	
	Cervical Cap/Dia- phragm			57170, A4261, A4266, X1B	Z30.018, Z30.019, Z30.40, Z30.49	
	Contracep- tive Patch			J7304, G8F	Z30.016, Z30.018, Z30.019, Z30.40, Z30.45, Z30.49	
	Contracep- tive Injection			J1050, 96372, G8C	Z30.013, Z30.018, Z30.019, Z30.40, Z30.42, Z30.49	
	Tubal Liga- tion			"00840, 00851, 58600, 58605, 58611, 58661, 58670, 58671, Rev Codes 370, 710, 360; for 25x, 270, 636, 637, and 300-See list of drugs, lab and sup- plies approved for this procedure. "	Z30.2	



United States Preventative Services Task Force (USPSTF) Recommendation or Institutes of Medicine Women's Preventive Recommendations	key word	Recommended age	USPSTF grade	CPT/HCPCS or Therapeutic Class Code (check for code validity based on service date)*	ICD-10	Reasonable Medical Management - limits applied. (If blank, limit was specified by USPSTF)
	Transcervi- cal Steriliza- tion			"00952, 58340, 58345, 58565, 74740, A4264, Rev Codes 370, 710, 360, for 25x, 270, 636, 637 and 300 see list of drugs and supplies on separate tab. "	Z30.2	
"Oral Contraceptives See Prev Meds Tab (formerly OTC Drugs)"	Oral con- traceptive / intravaginal			Therapeutic Class Codes G8A(not including GPI IDs starting with 2540),G9A, G9B		Pay generic without cost share.
"Emergency Contraception See Prev Meds Tab (formerly OTC Drugs)"	Emergency Contracep- tion			G8A with GPI Ids starting with 2540.		



United States Preventative Services Task Force (USPSTF) Recommendation or Institutes of Medicine Women's Preventive Recommendations	key word	Recommended age	USPSTF grade	CPT/HCPCS or Therapeutic Class Code (check for code validity based on service date)*	ICD-10	Reasonable Medical Management - limits applied. (If blank, limit was specified by USPSTF)
Screening for gestational diabetes mellitus (GDM) in asymptomatic pregnant women after 24 weeks of gestation (USPSTF), and at the first prenatal visit for pregnant women identified to be at high risk for diabetes (HRSA).	Gestational Diabetes			82947, 82950, 83036	009.00, 009.01,009.02,   009.03, 009.10, 009.11,   009.12, 009.13, 009.211,   009.212, 009.213, 009.219,   009.291, 009.292, 009.293,   009.299, 009.30, 009.31,   009.32, 009.33, 009.40,   009.41, 009.42, 009.43,   009.511, 009.512, 009.513,   009.519, 009.521, 009.522,   009.621, 009.613, 009.611,   009.621, 009.622, 009.623,   009.629, 009.70, 009.71,   009.72, 009.73, 009.811,   009.821, 009.822, 009.823,   009.829, 009.891, 009.892,   009.829, 009.891, 009.892,   009.83, 009.899, 009.90,   009.41, 009.41, 009.42,   009.823, 009.891, 009.813,   009.824, 009.813, 009.819,   009.829, 009.891, 009.802,   009.83, 009.899, 009.90,   009.40, 009A1, 009A2,   009A3, Z33.1, Z33.3, Z34.00,   Z34.80, Z34.81, Z34.82,   Z34.83, Z34.90, Z34.91,   Z34.92, Z34.93	



United States Preventative Services Task Force (USPSTF) Recommendation or Institutes of Medicine Women's Preventive Recommendations	key word	Recommended age	USPSTF grade	CPT/HCPCS or Therapeutic Class Code (check for code validity based on service date)*	ICD-10	Reasonable Medical Management - limits applied. (If blank, limit was specified by USPSTF)
Urine Pregnancy Test	Pregnancy test	Pregnancy test is medically necessary at change of birth control type.		81025	Z30.013, Z30.014, Z30.015, Z30.016, Z30.017, Z30.018, Z30.019, Z30.2, Z30.40, Z30.44, Z30.45, Z30.46, Z30.430, Z30.431, Z30.432, Z30.433	
Counseling for Contraception Options				99401, 99402, 99403, 99404	Z30.011, Z30.012, Z30.013, Z30.014, Z30.015, Z30.016, Z30.017, Z30.018, Z30.019, Z30.02, Z30.09, Z30.40, Z30.41, Z30.42, Z30.44, Z30.45, Z30.46, Z30.49, Z30.431, Z30.9	allowing one coun- seling session for adherence, remov- al, management of side-effects of contra- ception per year.
The USPSTF recommends screening for latent tuberculosis infection in populations at in- creased risk.	Tb	Adults	В	86480, 86580	Z11.1	
Bright Futures and the American Academy of Pediatrics recom- mends Tuberculin Screening on recognition of high risk factors.	Tb	1, 6, 12, 18 months; then annually.		86480, 86580	Z11.1	
Lab Draw	lab draw and han- dling fee			36415, 36416, 99000		covered without cost share when billed with an eligible HCR diagnosis
The USPSTF recommends screening for hepatitis C virus (HCV) infection in adults aged 18 to 79 years.	Нер С	18 to 79 years		86803, 86804, 87521, G0472	Z11.59	



United States Preventative Services Task Force (USPSTF) Recommendation or Institutes of Medicine Women's Preventive Recommendations	key word	Recommended age	USPSTF grade	CPT/HCPCS or Therapeutic Class Code (check for code validity based on service date)*	ICD-10	Reasonable Medical Management - limits applied. (If blank, limit was specified by USPSTF)
The USPSTF recommends annu- al screening for lung cancer with low-dose computed tomography (LDCT) in adults aged 50 to 80 years who have a 20 pack-year smoking history and currently smoke or have quit within the past 15 years. Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectan- cy or the ability or willingness to have curative lung surgery.	Lung Can- cer	"50-80	В	71271	Z87.891, F17.200, F17.201, F17.203, F17.208, F17.209, F17.210, F17.211, F17.213, F17.218, F17.219, F17.220, F17.221, F17.223, F17.228, F17.229, F17.290, F17.291, F17.293, F17.298, F17.299, Z12.2	both codes are by report and will be reviewed by MR for medical necessity based on policy lan- guage
"The USPSTF recommends that primary care clinicians apply fluo- ride varnish to the primary teeth of all infants and children starting at the age of primary tooth eruption See Prev Meds Tab (formerly OTC Drugs)"	fluoride varnish	6 mons- through age 5		99188, D1206		See other row(s) with keyword fluoride



United States Preventative Services Task Force (USPSTF) Recommendation or Institutes of Medicine Women's Preventive Recommendations	key word	Recommended age	USPSTF grade	CPT/HCPCS or Therapeutic Class Code (check for code validity based on service date)*	ICD-10	Reasonable Medical Management - limits applied. (If blank, limit was specified by USPSTF)
"The USPSTF recommends screening for hepatitis B virus (HBV) infection in adolescents and adults at increased risk for infection. Bright Futures expands the age range to newborn to 21 years. See Bright Futures Row for more information."	Hep B non pregnant		A	86706, 87340, 87341	Z11.59	See key word Hepati- tis B (pregnant)
"The USPSTF recommends the use of low-dose aspirin (81 mg/d) as preventive medication after 12 weeks of gestation in women who are at high risk for preeclampsia. See Prev Meds Tab (formerly OTC Drugs)"	low dose Aspirin		В	Prev code A on stand alone drug inquiry		prescription required
"The USPSTF recommends screening for hypertensive dis- orders in pregnant persons with blood pressure measurements throughout pregnancy.	hyperten- sive disor- ders preg- nant		В	99385, 99386, 99387, 99395, 99396, 99397		



United States Preventative Services Task Force (USPSTF) Recommendation or Institutes of Medicine Women's Preventive Recommendations	key word	Recommended age	USPSTF grade	CPT/HCPCS or Therapeutic Class Code (check for code validity based on service date)*	ICD-10	Reasonable Medical Management - limits applied. (If blank, limit was specified by USPSTF)
"The USPSTF recommends screening for high blood pressure in adults aged 18 years or older. The USPSTF recommends obtaining measurements outside of the clinical setting for diagnos- tic confirmation before starting treatment"	"Blood Pres- sure "	18 and over	A	93784, 93786, 93788, 93790, A4670	R03.0, Z01.30, Z01.31	
"The USPSTF recommends that clinicians prescribe a statin for the primary prevention of Cardio- vascular Disease for adults aged 40 to 75 years who have 1 or more CVD risk factors (i.e. dys- lipidemia, diabetes, hypertnsion, or smoking) and an estimated 10-year risk of a cardiovascular event of 10% or greater. •See Prev Meds Tab (formerly OTC Drugs) •See ACA Prevention Copay Waiver Criteria (on myprime.com or bcbsks.com medical policy page)"	Statin Preventive Medication	40 to 75	В	"Preventive Code H on stand alone drug inquiry"		



United States Preventative Services Task Force (USPSTF) Recommendation or Institutes of Medicine Women's Preventive Recommendations	key word	Recommended age	USPSTF grade	CPT/HCPCS or Therapeutic Class Code (check for code validity based on service date)*	ICD-10	Reasonable Medical Management - limits applied. (If blank, limit was specified by USPSTF)
The USPSTF recommends that clinicians offer pregnant persons effective behavioral counseling interventions aimed at promoting healthy weight gain and prevent- ing excess gestational weight gain in pregnancy.	"pregnancy weight counseling intervention"		В	97802, 97803, 97804	O09.00, O09.01, O09.02, O09.03, O09.10, O09.11, O09.12, O09.13, O09.211, O09.212, O09.213, O90.219, O09.291, O09.292, O09.293, O09.299, O09.30, O09.31, O09.32, O09.33, O09.40, O09.41, O09.42, O09.43, O09.511, O09.512, O09.513, O09.519, O09.521, O09.522, O09.523, O09.529, O09.611, O09.612, O09.613, O09.619, O09.621, O09.622, O09.623, O09.629, O09.70, O09.71, O09.72, O09.73, O09.811, O09.812, O09.813, O09.819, O09.821, O09.822, O09.823, O09.829, O09.891, O09.823, O09.829, O09.891, O09.822, O09.83, O09.899, O09.90, O09.91, O09.92, O09.93, O09.A0, O09A1, O09A2, O09A3, Z33.1, Z33.3, Z34.00, Z34.01, Z34.02, Z34.03, Z34.80, Z34.81, Z34.82, Z34.83, Z34.90, Z34.91, Z34.92, Z34.93	



#### **Immunization Schedule**

Vaccine type	CPT code	CPT description	Indication per CDC
Recommended Adult Schedule			
Tetanus, Diptheria, pertussis (Td/Tdap)	90714	Tetanus and diptheria toxoids(Td) adsorbed, perservative free when administered to individ- uals 7 years or older for IM use	
	90715	Tetanus and diptheria toxoids and acellular pertussis vaccine(Tdap) when administered to individuals 7 years or older for IM use	
Human Papillomaviirus(HPV)	90649	Human Pailloma vi- rus(HPV) vaccine, types 6,11,16, 18 (quadriva- lent) 3 dose schedule for intramuscular use	ages 9-26; 3 doses schedule
	90650	Human Papillomavi- rus(HPV) vaccine, types 16, 18 (bivalent) 3 dose schedule for intramuscu- lar use	
	90651	Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (HPV), 3 dose schedule, for intra- muscular use	



#### **Immunization Schedule**

Vaccine type	CPT code	CPT description	Indication per CDC
Varicella	90716	Varicella virus vaccine, live, for subcutaneous use	
Zoster	90736	Zoster(shingles) vaccine (HZV), live for subcu- taneous injection [Zos- tavax®]	Age 60 and over; 1 dose
	90750	Zoster (shingles) vac- cine (HZV), recombi- nant, subunit, adjuvant- ed, for intramuscular use [Shingrix®]	Age 50 and over; 2 doses (at ) and 2 to 6 months)
Measles, Mumps, rubella (MMR)	90707	Measles, mumps, and rubella virus vaccine (MMR), live, for SQ use	
	90710	Measles,mumps, ru- bella, and varicella vaccine(MMVR) live for subcutaneous use	Ages 19-49; one or 2 doses: ages 50->65 one dose
Influenza	90630	Influenza virus vaccine, quadrivalent, (IIV4) split virus, preservative free, for intradermal use	One dose annually
	90656	Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for IM use.	



#### **Immunization Schedule**

Vaccine type	CPT code	CPT description	Indication per CDC
	90658	Influenza virus vaccine, trivalent (IIV3), split virus, 0.5 mL dosage, for intramuscular use	One dose annually
	90660	Influenza virus vaccine, live for intranasal use	
	90661	Influenza virus vaccine, trivalent (ccIIV3), de- rived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for IM use	One dose annually
	90672	Influenza virus vaccine, quadrivalent, live, for intranasal use	
	90673	Influenza virus vac- cine, trivalent, derived from recombinant DNA (RIV3), hemagglutin- in(HA) protein only, pre- servative and antibiotic free, for intramuscular use	
	90674	Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cul- tures, subunit, preserv- ative and antibiotic free, 0.5 mL dosage, for IM use	


Vaccine type	CPT code	CPT description	Indication per CDC
	90682	Influenza virus vaccine, quadrivalent (RIV4), de- rived from recombinant DNA, hemagglutinin (HA) protein only, pre- servative and antibiotic free, for intramuscular use	Approved for use in adults 18 years of age and older
	90686	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for IM use	
	90688	Influenza virus vaccine, quadrivalent, split virus, 0.5 mL dosage, for IM use	One dose annually
	90662	Influenza virus vaccine, split virus, preservative free, enhanced immu- nogenicity via increased antigen content, for IM use	
	90694	Influenza virus vaccine, quadrivalent (alIV4), inactivated, adjuvanted, preservative free, 0.5 mL dosage, for intra- muscular use	



Vaccine type	CPT code	CPT description	Indication per CDC
	90756	Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cul- tures, subunit, antibiotic free, 0.5mL dosage, for intramuscular use	approved for use in persons 4 years of age and older.
Pneumococcal (polysaccharide)	90670	Pneumococcal conju- gate vaccine, 13 valent for IM use (deleted 1/31/2025 or before)	Ages 19-64; one or 2 doses: Ages >65 one dose
	90671	Pneumococcal conju- gate vaccine, 15 valent (PCV15), for intramus- cular use	Ages 18 and older
	90677	Pneumococcal conju- gate vaccine, 20 valent (PCV20), for intramus- cular use	Ages 18 and older
	90684	Pneumococcal con- jugate vaccine, 21 valent (PCV21), for intramuscular use	
	90732	Pneumococcal polysac- charide vaccine, 23-va- lent adult or immunosup- presed patient dosage, when administered to individuals 2 years or older	



Vaccine type	CPT code	CPT description	Indication per CDC
Hepatitis A	90632	Hepatitis A vaccine, adult dosage, for intra- muscular use	All Adults Ages 19->65; 2 doses
	90636	Hepatitis A and Hepatitis B vaccine(HepA-HepB) adult dosage, for intra- muscular use	



Vaccine type	CPT code	CPT description	Indication per CDC
Hepatitis A and B	90636	Hepatitis A and Hepatitis B vaccine(HepA-HepB) adult dosage, for intra- muscular use	
Hepatitis B	90739	Hepatitis B vaccine (HepB), CpG-adjuvant- ed, adult dosage, 2 dose or 4 dose schedule, for intramuscular use [Heplisav®]	
	90740	Hepatitis B vaccine, dialysis or immunosup- pressed patient dos- age(3 dose schedule) for intramuscular use	"All Adults Ages 18->65; 3 doses
	90746	Hepatitis B vaccine, adult dosage, for intra- muscular use	
	90747	Hepatitis B vaccine, dialysis or immunosup- pressed patient dos- age(4 dose schedule) for intramuscular use	"
	90759	Hepatitis B vaccine, 3-antigen (S, Pre-S1, Pre-S2), 10 mcg dos- age, 3 dose schedule, for intramuscular use	



Vaccine type	CPT code	CPT description	Indication per CDC
"Meningococcal "	90619	Meningococcal con- jugate vaccine, sero- groups A, C, W, Y, quad- rivalent, tetanus toxoid carrier (MenACWY-TT), for intramuscular use.	1 or 2 doses given to high-risk adults.
	90620	Meningococcal re- combinant protein and outer membrane vesicle vaccine, Serogroup B, 2 dose schedule, for intramuscular use	
	90621	Meningococcal recombi- nant lipoprotein vaccine, Serogroup B(MenB), 3 dose schedule, for intra- muscular use	
	90623	Meningococcal pentava- lent vaccine, conjugated Men A, C, W, Y-tetanus toxoid carrier, and Men- B-FHbp, for intramuscu- lar use	



Vaccine type	CPT code	CPT description	Indication per CDC
	90733	Meningococcal poly- saccharide vaccine(any groups for subcutaneous use	one or more doses all adults
	90734	Meningococcal con- jugate vaccine, se- rogroups A,C,Y and W-135, quadrivalent (MCV4 or MenACWY), for Intramuscular use (deleted 1/31/2025 or before)	one or more doses all adults
RSV (Respiratory Syncytial Virus)	90678	Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use	"One dose for adults 60 years and older, as well as adults in their second or third trimester of pregnancy "
	90679	Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intra- muscular use	
	90683	Rrespiratory syncytial virus vaccine, MRNA lipid nanoparticles, for intramuscular use	



Vaccine type	CPT code	CPT description	Indication per CDC
Smallpox and monkeypox	90611	Smallpox and monkey- pox vaccine, attenuat- ed vaccinia virus, line, non-replicating, pre- servative free, 0.5 mL dosage, suspensin, for subcutaneous use	
	90622	Vaccinia (smallpox) virus vaccine, live, lyophilized, 0.3 mL dosage, for per- cutaneous use	
Recommended childhood vaccinations			
"Diptheria, Tetanus, Pertussis, Polio, Haemophilus, Influenza B, and Hepati- tis B "	90697	Diphtheria, tetanus toxoids, acellular pertus- sis vaccine, inactivated poliovirus vaccine, Hae- mophilus influenza type b PRP-OMP conjugate vaccine, and hepatitis B vaccine (DTaP-IPV-Hib- HepB), for intramuscular use	Recommended doses at 2 months, 4 months, and 6 months - total of three doses.
Influenza vaccine	90630	Influenza virus vaccine, quadrivalent, (IIV4) split virus, preservative free, for intradermal use	annual
	90653	Influenza vaccine, in- activated (IIV), subunit, adjuvanted, for intra- muscular use	annual



Vaccine type	CPT code	CPT description	Indication per CDC
	90654	Influenza virus vaccine, split virus, preservative free for intradermal use	at least annually; 2 doses are sometimes required if under age
	90655	Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.25 mL dosage, for IM use.	9 receiving Influenza vaccine for the 1st time. Hib is given at 2 mon, 4 mon, 6 mon, and 12-15 months.
	90656	Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for IM use.	
	90657	Influenza virus vaccine, trivalent (IIV3), split virus, 0.25 mL dosage, for IM use.	at least annually; 2 doses are sometimes required if under age 9 receiving Influenza vaccine for the 1st time. Hib is given at 2 mon, 4 mon, 6 mon, and 12-15 months.
	90661	Influenza virus vaccine, trivalent (ccIIV3), de- rived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for IM use	
	90672	Influenza virus vaccine, quadrivalent, live for intranasal use	



Vaccine type	CPT code	CPT description	Indication per CDC
	90673	Influenza virus vac- cine, trivalent, derived from recombinant DNA (RIV3), hemagglutin- in(HA) protein only, pre- servative and antibiotic free, for intramuscular use	
	90685	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for IM use.	
	90686	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for IM use	
	90687	Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, for IM use	
	90756	Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cul- tures, subunit, antibiotic free, 0.5mL dosage, for intramuscular use	approved for use in persons 4 years of age and older.



Vaccine type	CPT code	CPT description	Indication per CDC
	90688	Influenza virus vaccine, quadrivalent, split virus, 0.5 mL dosage, for IM use	
	90694	Influenza virus vaccine, quadrivalent (aIIV4), inactivated, adjuvanted, preservative free, 0.5 mL dosage, for intra- muscular use	



Vaccine type	CPT code	CPT description	Indication per CDC
Tetanus, Diptheria, Pertussis(Tdap, Dtap)	90696	Diptheria, tetanus tox- oids, acellular pertussis vaccine and poliovirus vaccine, inactivated(D- tap-IPV) when adminis- tered to children 4-6 for IM use	
	90698	Diptheria, tetanus tox- oids, acellular pertussis vaccine, haemophilus influenza Type B and poliovirus vaccine, inac- tivated(Dtap-Hib-IPV) for IM use	DTap at 2,4,6,15-18 months, 4-6 years. Tdap 11-12 and 13-18 years. "
	90700	Diptheria, tetanus toxoids, and acellular pertussis vaccine(Dtap) when administered to individuals younger than 7 years, for IM use	
	90702	Diptheria and tetanus toxoids (DT) when ad- ministered to individuals younter than 7 years for IM use (deleted 12/30/2024)	



Vaccine type	CPT code	CPT description	Indication per CDC
	90714	Tetanus and diptheria toxoids(Td) adsorbed, perservative free when administered to individ- uals 7 years or older for IM use	
	90715	Tetanus and diptheria toxoids and acellular pertussis vaccine(Tdap) when administered to individuals 7 years or older for IM use	DTap at 2,4,6,15-18 months, 4-6 years. Tdap 11-12 and 13-18 years. "
	90723	Diptheria, tetanus toxoid, and acellular pertussis vaccine, Hep- atitis B, and poliovirus vaccine, inactivated(D- taP-HepB-IPV) for IM use	
Rotavirus	90680	Rotavirus vaccine, pen- tavalent, 3 dose sched- ule, live for oral use	2, 4, and 6 months.
	90681	Rotavirus vaccine,hu- man, attenuated, 2 dose schedule, live for oral use	
Hepatitis B	90743	Hepatitis B vaccine, ad- olescent (2 dose sched- ule) for IM use	Birth, between 1-2 months, between 6-18 months: age 7-18; 3 dose schedule if not previously vaccinated



Vaccine type	CPT code	CPT description	Indication per CDC
	90744	Hepatitis B vaccine, pediatric/adolescent (3 dose schedule) for IM use	Birth, between 1-2 months, between 6-18 months: age 7-18; 3 dose schedule if not previously vaccinated
	90748	Hepatitis B and Hemophilis influenza b vaccine(HepB-Hib) for IM use	
Smallpox and monkepox	90611	Smallpox and monkey- pox vaccine, attenuat- ed vaccinia virus, line, non-replicating, pre- servative free, 0.5 mL dosage, suspensin, for subcutaneous use	
"Meningococcal "	90619	Meningococcal con- jugate vaccine, sero- groups A, C, W, Y, quad- rivalent, tetanus toxoid carrier (MenACWY-TT), for intramuscular use.	Routine vaccination recommended anytime after age 11 with a booster dose at age 16. Recommended for persons at in- creased risk of disease beginning at 2 months.
	90620	Meningococcal re- combinant protein and outer membrane vesicle vaccine, Serogroup B, 2 dose schedule, for intramuscular use	



Vaccine type	CPT code	CPT description	Indication per CDC
	90621	Meningococcal recombi- nant lipoprotein vaccine, Serogroup B(MenB), 3 dose schedule, for intra- muscular use	
	90623	Meningococcal pentava- lent vaccine, conjugated Men A, C, W, Y-tetanus toxoid carrier, and Men- B-FHbp, for intramuscu- lar use	
	90734	Meningococcal con- jugate vaccine, se- rogroups A,C,Y and W-135, quadrivalent (MCV4 or MenACWY), for Intramuscular use	Routine vaccination recommended anytime after age 11 with a booster dose at age 16. Recommended for persons at in- creased risk of disease beginning at 2 months.
Pneumococcal	90670	Pneumococcal conju- gate vaccine, 13 valent for IM use	Minimum age 12 months, 2 doses through age 18 years
	90671	Pneumococcal conju- gate vaccine, 15 valent (PCV15), for intramus- cular use	Administered at 2, 4, 6 months and then again between 12 and 15 months.
	90677	Pneumococcal conju- gate vaccine, 20 valent (PCV20), for intramus- cular use	Ages 6 weeks of age and older



Vaccine type	CPT code	CPT description	Indication per CDC
	90732	Pneumococcal pol- ysacharide vaccine, 23-valent, adult or immunosuppressed patient dosage when administered to individ- uals 2 years or older, for subcutaneous or IM use.	Minimum age 12 months, 2 doses through age 18 years
Measles, Mumps, rubella (MMR)	90707	Measles, mumps, and rubella virus vaccine(M- MR), live for subcutane- ous use	
	90710	Measles,mumps, ru- bella, and varicella vaccine(MMVR) live for subcutaneous use	Minimum age 12 months, 2nd dose around ages 4-6; ages after 6 to catch-up
Varicella	90716	Varicella virus vaccine, live, for subcutaneous use	
Hepatitis A	90633	Hepatitis A vaccine, pediatric/adolescent dosage-2 dose sched- ule, for IM use	Administered at 2, 4, 6 months and if 4 dose schedule again
	90634	Hepatitis A vaccine, pediatric/adolescent dosage-3 dose sched- ule, for IM use	between 12 and 15 months.



Vaccine type	CPT code	CPT description	Indication per CDC
Hemophilis influenza type b	90647	Hemophilius influenza b vaccine( Hib), PRP- OMP conjugate(3 dose schedule) for IM use	
	90648	Hemophilius influenza b vaccine( Hib), PRP-T conjugate(4 dose sched- ule) for IM use	3 doses by age 4 years starting at age 2 months. Final dose af-
Inactivated poliovirus	90696	Diptheria, tetanus tox- oids, acellular pertussis vaccine and poliovirus vaccine, inactivated(D- tap-IPV) when adminis- tered to children 4-6 for IM use	ter age 4. Can be given as combo vaccine Dtap-IPV or alone.
	90698	Diptheria, tetanus tox- oids, acellular pertussis vaccine, haemophilus influenza Type B and poliovirus vaccine, inac- tivated(Dtap-Hib-IPV) for IM use	
	90713	Poliovirus vaccine, inac- tivated(IPV), for subcu- taneous or IM use	3 dose schedule starting at age 11
Human Papillomavirus(HPV)	90649	Human Papillomavi- rus(HPV) vaccine, types 6,11,16, 18 (quadriva- lent) 3 dose schedule for intramuscular use	



Vaccine type	CPT code	CPT description	Indication per CDC
	90650	Human Papillomavi- rus(HPV) vaccine, types 16, 18 (bivalent) 3 dose schedule for intramuscu- lar use	ages 9-26; 3 doses schedule
	90651	Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (HPV), 3 dose schedule, for intra- muscular use	
RSV	90380	Respiratory syncytial virus, monoclonal an- tibody, seasonal dose; 0.5 mL dosage, for intra- muscular use	
	90381	1 mL dosage, for intra- muscular use	
Traveler's Vaccination Recommendations			
Varicella Vaccine	90716	Varicella virus vaccine, live, for subcutaneous use	
Measles, Mumps, Rubella (MMR) vac- cination	90707	Measles, mumps, and rubella virus vaccine(M- MR), live for subcutane- ous use	



Vaccine type	CPT code	CPT description	Indication per CDC
	90710	Measles,mumps, ru- bella, and varicella vaccine(MMVR) live for subcutaneous use	
Hepatitis A Vaccine	90633	Hepatitis A vaccine, pediatric/adolescent dosage-2 dose sched- ule, for IM use	
	90634	Hepatitis A vaccine, pediatric/adolescent dosage-3 dose sched- ule, for IM use	
	90632	Hepatitis A vaccine, adult dosage, for intra- muscular use	
Hepatitis A and B Vaccine	90636	Hepatitis A and Hepatitis B vaccine(HepA-HepB) adult dosage, for intra- muscular use	
Hepatitis B vaccine	90743	Hepatitis B vaccine, ad- olescent (2 dose sched- ule) for IM use	
	90744	Hepatitis B vaccine, pediatric/adolescent (3 dose schedule) for IM use	
	90748	Hepatitis B and Hemophilis influenza b vaccine(HepB-Hib) for IM use	



Vaccine type	CPT code	CPT description	Indication per CDC
	90636	Hepatitis A and Hepatitis B vaccine(HepA-HepB) adult dosage, for intra- muscular use	
	90740	Hepatitis B vaccine, dialysis or immunosup- pressed patient dos- age(3 dose schedule) for intramuscular use	
	90746	Hepatitis B vaccine, adult dosage, for intra- muscular use	
	90747	Hepatitis B vaccine, dialysis or immunosup- pressed patient dos- age(4 dose schedule) for intramuscular use	
Meningococcal vaccination	90733	Meningococcal poly- saccharide vaccine(any groups for subcutaneous use	
	90734	Meningococcal con- jugate vaccine, se- rogroups A,C,Y and W-135, quadrivalent (MCV4 or MenACWY), for Intramuscular use	



Vaccine type	CPT code	CPT description	Indication per CDC
Immunization Administration codes			
	90471	Immunization adminis- tration (includes per- cutaneous, intradermal, subcutaneous or intra- muscular); 1 vaccine (single or combination vaccine/toxoid)	
	90472	*each additional vac- cine(single or combina- tion vaccine/toxoid) list separately in addition to code for primary proce- dure.	
	90473	Immunization adminis- tration by intranasal or oral route; 1 vaccine(s- ingle or combination vaccine/toxoid)	
	90474	*each additional vac- cine(single or combina- tion vaccine/toxoid)(list separately ina ddition to code for primary proce- dure)	
	G0008	Administration of influen- za virus vaccine	
	G0009	Administration of pneu- mococcal vaccine	
	G0010	Administration of hepati- tis B vaccine	



Vaccine type	CPT code	CPT description	Indication per CDC
	90460	Immunization admin- istration through 18 years of age via any route of administration, with counseling by phy- sician or other qualified health care profession- al: first vaccine/toxoid component. (new code 01/01/2011)	
	90461	*each additional vac- cine/toxoid component (list separately in addi- tion to the code for pri- mary procedure). (new code 01/01/2011)	
COVID-19 Vaccination/Administration Codes			
	90480	Immunization adminis- tration by intramuscular injection of severe acute respiratory syndrome coranavirus 2 (SARS- CoV-2)(coronavirus disease [COVID-19]) vaccine, single dose	



Vaccine type	CPT code	CPT description	Indication per CDC
	91304	"Severe acute respira- tory syndrome corona- virus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike pro- tein nanoparticle, sap- onin-based adjuvant, 5 mcg/0.5 mL dosage, for intramuscular use.	
	91318	"Severe acute respirato- ry syndrome coronavirus 2 (SARSCoV-2) (coro- navirus disease [COV- ID-19]) vaccine, mR- NA-LNP, spike protein, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-su- crose formulation, for intramuscular use"	



Vaccine type	CPT code	CPT description	Indication per CDC
	91319	"Severe acute respirato- ry syndrome coronavirus 2 (SARSCoV-2) (coro- navirus disease [COV- ID-19]) vaccine, mR- NA-LNP, spike protein, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-su- crose formulation, for intramuscular use"	
	91320	"Severe acute respirato- ry syndrome coronavirus 2 (SARSCoV-2) (coro- navirus disease [COV- ID-19]) vaccine, mR- NA-LNP, spike protein, 30 mcg/0.2 mL dosage, diluent reconstituted, tris-su- crose formulation, for intramuscular use"	
	91321	"acute respiratory syn- drome coronavirus 2 (SARSCoV-2) (coronavi- rus disease [COVID-19]) vaccine, mRNALNP, 25 mcg/0.25 mL dosage, for intramuscular use "	



Vaccine type	CPT code	CPT description	Indication per CDC
	91322	"acute respiratory syn- drome coronavirus 2 (SARSCoV-2) (coronavi- rus disease [COVID-19]) vaccine, mRNALNP, 50 mcg/0.5 mL dosage, for intramuscular use "	



REV_CD	PROC_CD	HCPCS_CD_DS		
0636	90658	INFLUENZA VIRUS VACCINE, SPLIT VIRUS, WHEN ADMINISTERED TO INDI- VIDUALS 3 YEARS		
0636	90732	PNEUMOCOCCAL POLYSACCHARIDE VACCINE, 23-VALENT, ADULT OR IM- MUNOSUPPRESSED		
0270	99070	SUPPLIES AND MATERIALS (EXCEPT SPECTACLES), PROVIDED BY THE PHYSICIAN OVER AND		
0279	99070	SUPPLIES AND MATERIALS (EXCEPT SPECTACLES), PROVIDED BY THE PHYSICIAN OVER AND		
0250	A4216	STERILE WATER, SALINE AND/OR DEXTROSE, DILUENT/FLUSH, 10 ML		
0272	A4216	STERILE WATER, SALINE AND/OR DEXTROSE, DILUENT/FLUSH, 10 ML		
0636	A4216	STERILE WATER, SALINE AND/OR DEXTROSE, DILUENT/FLUSH, 10 ML		
0250	A4218	STERILE SALINE OR WATER, METERED DOSE DISPENSER, 10 ML		
0259	A4218	STERILE SALINE OR WATER, METERED DOSE DISPENSER, 10 ML		
0272	A6402	GAUZE, NON-IMPREGNATED, STERILE, PAD SIZE 16 SQ. IN. OR LESS, WITHOUT		
0272	C1726	CATHETER, BALLOON DILATATION, NON-VASCULAR		
0278	C1726	CATHETER, BALLOON DILATATION, NON-VASCULAR		
0279	C1726	CATHETER, BALLOON DILATATION, NON-VASCULAR		
0272	C1773	RETRIEVAL DEVICE, INSERTABLE (USED TO RETRIEVE FRACTURED MEDI- CAL		
0278	C1773	RETRIEVAL DEVICE, INSERTABLE (USED TO RETRIEVE FRACTURED MEDI- CAL		
0636	J0290	INJECTION, AMPICILLIN SODIUM, 500 MG		
0636	J0295	INJECTION, AMPICILLIN SODIUM/SULBACTAM SODIUM, PER 1.5 GM		
0259	J0330	INJECTION, SUCCINYLCHOLINE CHLORIDE, UP TO 20 MG		



REV_CD	PROC_CD	HCPCS_CD_DS			
0636	J0330	INJECTION, SUCCINYLCHOLINE CHLORIDE, UP TO 20 MG			
0250	J0461	INJECTION, ATROPINE SULFATE, 0.01 MG			
0636	J0461	INJECTION, ATROPINE SULFATE, 0.01 MG			
0636	J0500	INJECTION, DICYCLOMINE HCL, UP TO 20 MG			
0636	J0595	INJECTION, BUTORPHANOL TARTRATE, 1 MG			
0259	J0690	INJECTION, CEFAZOLIN SODIUM, 500 MG			
0636	J0690	INJECTION, CEFAZOLIN SODIUM, 500 MG			
0250	J0694	INJECTION, CEFOXITIN SODIUM, 1 GM			
0636	J0696	INJECTION, CEFTRIAXONE SODIUM, PER 250 MG			
0636	J0780	INJECTION, PROCHLORPERAZINE, UP TO 10 MG			
0636	J1170	INJECTION, HYDROMORPHONE, UP TO 4 MG			
0250	J1200	INJECTION, DIPHENHYDRAMINE HCL, UP TO 50 MG			
0636	J1200	INJECTION, DIPHENHYDRAMINE HCL, UP TO 50 MG			
0636	J1260	INJECTION, DOLASETRON MESYLATE, 10 MG			
0636	J1335	INJECTION, ERTAPENEM SODIUM, 500 MG			
0250	J1580	INJECTION, GARAMYCIN, GENTAMICIN, UP TO 80 MG			
0259	J1580	INJECTION, GARAMYCIN, GENTAMICIN, UP TO 80 MG			
0636	J1580	INJECTION, GARAMYCIN, GENTAMICIN, UP TO 80 MG			
0258	J1610	INJECTION, GLUCAGON HYDROCHLORIDE, PER 1 MG			
0259	J1610	INJECTION, GLUCAGON HYDROCHLORIDE, PER 1 MG			
0636	J1610	INJECTION, GLUCAGON HYDROCHLORIDE, PER 1 MG			
0636	J1626	INJECTION, GRANISETRON HYDROCHLORIDE, 100 MCG			
0259	J1642	INJECTION, HEPARIN SODIUM, (HEPARIN LOCK FLUSH), PER 10 UNITS			
0636	J1642	INJECTION, HEPARIN SODIUM, (HEPARIN LOCK FLUSH), PER 10 UNITS			



REV_CD	PROC_CD	HCPCS_CD_DS			
0636	J1644	INJECTION, HEPARIN SODIUM, PER 1000 UNITS			
0259	J1650	INJECTION, ENOXAPARIN SODIUM, 10 MG			
0636	J1650	INJECTION, ENOXAPARIN SODIUM, 10 MG			
0250	J1815	INJECTION, INSULIN, PER 5 UNITS			
0250	J1885	INJECTION, KETOROLAC TROMETHAMINE, PER 15 MG			
0259	J1885	INJECTION, KETOROLAC TROMETHAMINE, PER 15 MG			
0636	J1885	INJECTION, KETOROLAC TROMETHAMINE, PER 15 MG			
0636	J1956	INJECTION, LEVOFLOXACIN, 250 MG			
0250	J2001	INJECTION, LIDOCAINE HCL FOR INTRAVENOUS INFUSION, 10 MG			
0259	J2001	INJECTION, LIDOCAINE HCL FOR INTRAVENOUS INFUSION, 10 MG			
0636	J2001	INJECTION, LIDOCAINE HCL FOR INTRAVENOUS INFUSION, 10 MG			
0250	J2175	INJECTION, MEPERIDINE HYDROCHLORIDE, PER 100 MG			
0259	J2175	INJECTION, MEPERIDINE HYDROCHLORIDE, PER 100 MG			
0636	J2175	INJECTION, MEPERIDINE HYDROCHLORIDE, PER 100 MG			
0636	J2180	INJECTION, MEPERIDINE AND PROMETHAZINE HCL, UP TO 50 MG			
0250	J2250	INJECTION, MIDAZOLAM HYDROCHLORIDE, PER 1 MG			
0251	J2250	INJECTION, MIDAZOLAM HYDROCHLORIDE, PER 1 MG			
0259	J2250	INJECTION, MIDAZOLAM HYDROCHLORIDE, PER 1 MG			
0636	J2250	INJECTION, MIDAZOLAM HYDROCHLORIDE, PER 1 MG			
0259	J2270	INJECTION, MORPHINE SULFATE, UP TO 10 MG			
0636	J2270	INJECTION, MORPHINE SULFATE, UP TO 10 MG			
0636	J2275	INJECTION, MORPHINE SULFATE (PRESERVATIVE-FREE STERILE SOLU- TION), PER			
0259	J2300	INJECTION, NALBUPHINE HYDROCHLORIDE, PER 10 MG			



REV_CD	PROC_CD	HCPCS_CD_DS			
0636	J2300	INJECTION, NALBUPHINE HYDROCHLORIDE, PER 10 MG			
0259	J2310	INJECTION, NALOXONE HYDROCHLORIDE, PER 1 MG			
0636	J2310	INJECTION, NALOXONE HYDROCHLORIDE, PER 1 MG			
0259	J2370	INJECTION, PHENYLEPHRINE HCL, UP TO 1 ML			
0636	J2370	INJECTION, PHENYLEPHRINE HCL, UP TO 1 ML			
0636	J2405	INJECTION, ONDANSETRON HYDROCHLORIDE, PER 1 MG			
0259	J2550	INJECTION, PROMETHAZINE HCL, UP TO 50 MG			
0636	J2550	INJECTION, PROMETHAZINE HCL, UP TO 50 MG			
0636	J2710	INJECTION, NEOSTIGMINE METHYLSULFATE, UP TO 0.5 MG			
0250	J2765	INJECTION, METOCLOPRAMIDE HCL, UP TO 10 MG			
0259	J2765	INJECTION, METOCLOPRAMIDE HCL, UP TO 10 MG			
0636	J2765	INJECTION, METOCLOPRAMIDE HCL, UP TO 10 MG			
0636	J2780	INJECTION, RANITIDINE HYDROCHLORIDE, 25 MG			
0255	J3010	INJECTION, FENTANYL CITRATE, 0.1 MG			
0259	J3010	INJECTION, FENTANYL CITRATE, 0.1 MG			
0636	J3010	INJECTION, FENTANYL CITRATE, 0.1 MG			
0636	J3360	INJECTION, DIAZEPAM, UP TO 5 MG			
0636	J3370	INJECTION, VANCOMYCIN HCL, 500 MG			
0259	J3410	INJECTION, HYDROXYZINE HCL, UP TO 25 MG			
0636	J3480	INJECTION, POTASSIUM CHLORIDE, PER 2 MEQ			
0250	J7030	INFUSION, NORMAL SALINE SOLUTION, 1000 CC			
0258	J7030	INFUSION, NORMAL SALINE SOLUTION, 1000 CC			
0259	J7030	INFUSION, NORMAL SALINE SOLUTION, 1000 CC			
0270	J7030	INFUSION, NORMAL SALINE SOLUTION , 1000 CC			



REV_CD	PROC_CD	HCPCS_CD_DS			
0636	J7030	INFUSION, NORMAL SALINE SOLUTION , 1000 CC			
0250	J7040	INFUSION, NORMAL SALINE SOLUTION, STERILE (500 ML=1 UNIT)			
0258	J7040	INFUSION, NORMAL SALINE SOLUTION, STERILE (500 ML=1 UNIT)			
0636	J7040	INFUSION, NORMAL SALINE SOLUTION, STERILE (500 ML=1 UNIT)			
0258	J7042	5% DEXTROSE/NORMAL SALINE (500 ML = 1 UNIT)			
0258	J7050	INFUSION, NORMAL SALINE SOLUTION , 250 CC			
0259	J7050	INFUSION, NORMAL SALINE SOLUTION , 250 CC			
0636	J7050	INFUSION, NORMAL SALINE SOLUTION , 250 CC			
0636	J7060	5% DEXTROSE/WATER (500 ML = 1 UNIT)			
0636	J7070	INFUSION, D5W, 1000 CC			
0250	J7120	RINGERS LACTATE INFUSION, UP TO 1000 CC			
0258	J7120	RINGERS LACTATE INFUSION, UP TO 1000 CC			
0259	J7120	RINGERS LACTATE INFUSION, UP TO 1000 CC			
0270	J7120	RINGERS LACTATE INFUSION, UP TO 1000 CC			
0636	J7120	RINGERS LACTATE INFUSION, UP TO 1000 CC			
0250	J7613	ALBUTEROL, INHALATION SOLUTION, FDA-APPROVED FINAL PRODUCT,			
0250	J7620	ALBUTEROL, UP TO 2.5 MG AND IPRATROPIUM BROMIDE, UP TO 0.5 MG,			
0636	S0020	INJECTION, BUPIVICAINE HYDROCHLORIDE, 30 ML			
0258	S5010	5% DEXTROSE AND 45% NORMAL SALINE, 1000 ML			
250	J2704	Injection, propofol, 10 mg (use for Diprivan)			
258	J2704	Injection, propofol, 10 mg (use for Diprivan)			
259	J2704	Injection, propofol, 10 mg (use for Diprivan)			
636	J2704	Injection, propofol, 10 mg (use for Diprivan)			



# These are the drugs and supplies to be covered with no member cost sharing when billed as part of outpatient tubal ligation

REV_CD	PROC_CD	HCPCS_CD_DS			
0300	36415	COLLECTION OF VENOUS BLOOD BY VENIPUNCTURE			
0300	81025	URINE PREGNANCY TEST, BY VISUAL COLOR COMPARSION METHODS			
	84702	GONADOTROPIN, CHORIONIC (Hcg), QUANTITATIVE			
0300	85014	BLOOD COUNT;HEMATOCRIT(HCT)			
0300	85018	BLOOD COUNT; HMEOGLOBIN(HGB)			
	85025	BLOOD COUNT; COMPLETE (CBC) AUTOMATED(HBG, HCT, RBC,WBC AND PLATELET COUND) AND AUTOMATED DIFFERENTIAL WBC COUNT			
0300	85027	BLOOD COUNT; COMPLETE (CBC) AUTOMATED(HBG, HCT, RBC,WBC AND PLATELET COUNT)			
	87491	CHLAMYDIA TRACHOMATIS, AMPLIFIED PROBE TECHNIQUE			
	87591	NEISSERIA GONORRHEOEAE, AMPLIFIED PROBE TECHNIQUE			
	88302	SURGICAL PATHOLOGY, GROSS AND MICROSCOPIC EXAMINATION			
0636	90714	TETANUS AND DIPHTHERIA TOXOIDS(Td)ADSORBED, PRESERVATIVE FREE			
	A4550	SURIGICAL TRAYS			
0250	J0330	INJECTION, SUCCINYLCHOLINE CHLORIDE, UP TO 20 MG			
0636	J0461	INJECTION, ATROPINE SULFATE, 0.01 MG			
0250	J0690	INJECTION, CEFAZOLIN SODIUM, 500 MG			
0250	J0696	INJECTION, CEFTRIAXONE SODIUM, PER 250 MG			
0636	J0744	INJECTION, CIPROFLOXACIN FOR INTRAVENOUS INFUSION, 200 MG			
0636	J0780	INJECTION, PROCHLORPERAZINE, UP TO 10 MG			
0636	J1094	INJECTION, DEXAMETHASONE ACETATE, 1 MG			
0250	J1100	INJECTION, DEXAMETHASONE SODIUM PHOSPHATE, 1 MG			
0636	J1170	INJECTION, HYDROMORPHONE, UP TO 4 MG			
0250	J1200	INJECTION, DIPHENHYDRAMINE HCL, UP TO 50 MG			
0636	J1580	INJECTION, GARAMYCIN, GENTAMICIN, UP TO 80 MG			



# These are the drugs and supplies to be covered with no member cost sharing when billed as part of outpatient tubal ligation

REV_CD	PROC_CD	HCPCS_CD_DS			
0636	J1626	INJECTION, GRANISETRON HYDROCHLORIDE, 100 MCG			
0636	J1644	INJECTION, HEPARIN SODIUM, PER 1000 UNITS			
0259	J1650	INJECTION, ENOXAPARIN SODIUM, 10 MG			
0250	J1790	INJECTION, DROPERIDOL, UP TO 5 MG			
0250	J1885	INJECTION, KETOROLAC TROMETHAMINE, PER 15 MG			
0636	J1956	INJECTION, LEVOFLOXACIN, 250 MG			
0259	J2001	INJECTION, LIDOCAINE HCL FOR INTRAVENOUS INFUSION, 10 MG			
0250	J2175	INJECTION, MEPERIDINE HYDROCHLORIDE, PER 100 MG			
0259	J2180	INJECTION, MEPERIDINE AND PROMETHAZINE HCL, UP TO 50 MG			
0250	J2250	INJECTION, MIDAZOLAM HYDROCHLORIDE, PER 1 MG			
0250	J2270	INJECTION, MORPHINE SULFATE, UP TO 10 MG			
0636	J2300	INJECTION, NALBUPHINE HYDROCHLORIDE, PER 10 MG			
0250	J2310	INJECTION, NALOXONE HYDROCHLORIDE, PER 1 MG			
0636	J2370	INJECTION, PHENYLEPHRINE HCL, UP TO 1 ML			
0259	J2405	INJECTION, ONDANSETRON HYDROCHLORIDE, PER 1 MG			
0250	J2550	INJECTION, PROMETHAZINE HCL, UP TO 50 MG			
0636	J2597	INJECTION, DESMOPRESSIN ACETATE, PER 1 MCG			
0250	J2710	INJECTION, NEOSTIGMINE METHYLSULFATE, UP TO 0.5 MG			
0250	J2765	INJECTION, METOCLOPRAMIDE HCL, UP TO 10 MG			
0636	J2780	INJECTION, RANITIDINE HYDROCHLORIDE, 25 MG			
0636	J2930	INJECTION, METHYLPREDNSILONE SODIUM SUCCINATE, UP TO 40 MG			
0250	J3010	INJECTION, FENTANYL CITRATE, 0.1 MG			
	J3360	INJECTION, DIAZEPAM, UP TO 5 MG			
0636	J3410	INJECTION, HYDROXYZINE HCL, UP TO 25 MG			



# These are the drugs and supplies to be covered with no member cost sharing when billed as part of outpatient tubal ligation

REV_CD	PROC_CD	HCPCS_CD_DS			
0250	J7030	INFUSION, NORMAL SALINE SOLUTION, 1000 CC			
0258	J7040	INFUSION, NORMAL SALINE SOLUTION, STERILE (500 ML=1 UNIT)			
0636	J7050	INFUSION, NORMAL SALINE SOLUTION , 250 CC			
0258	J7060	5% DEXTROSE/WATER (500 ML = 1 UNIT)			
0250	J7120	RINGERS LACTATE INFUSION, UP TO 1000 CC			
0250	J7613	ALBUTEROL, INHALATION SOLUTION, FDA APPROVED FINAL PRODUCT, NONCOMPOUNDED, ADMINSTERED THROUGH DME UNIT DOSE, 1 MG			
0250	S0020	INJECTION, BUPIVICAINE HYDROCHLORIDE, 30 ML			
0259	S0028	INJECTION, FAMOTIDINE, 20 MG			
0250	S0077	INJECTION, CLINDAMYCIN PHOSPHATE, 300 MG			



# These are the drugs and supplies to be covered with no member cost sharing when billed as outpatient transcervical sterilization

REV_CD	PROC_CD	HCPCS_CD_DS			
0300	36415	COLLECTION OF VENOUS BLOOD BY VENIPUNCTURE			
0300	81025	URINE PREGNANCY TEST, BY VISUAL COLOR COMPARSION METHODS			
	84702	GONADOTROPIN, CHORIONIC (Hcg), QUANTITATIVE			
0300	85014	BLOOD COUNT;HEMATOCRIT(HCT)			
0300	85018	BLOOD COUNT; HMEOGLOBIN(HGB)			
	85025	BLOOD COUNT; COMPLETE (CBC) AUTOMATED(HBG, HCT, RBC,WBC AND PLATE- LET COUND) AND AUTOMATED DIFFERENTIAL WBC COUNT			
0300	85027	BLOOD COUNT; COMPLETE (CBC) AUTOMATED(HBG, HCT, RBC,WBC AND PLATE- LET COUNT)			
	87491	CHLAMYDIA TRACHOMATIS, AMPLIFIED PROBE TECHNIQUE			
	87591	NEISSERIA GONORRHEOEAE, AMPLIFIED PROBE TECHNIQUE			
	88302	SURGICAL PATHOLOGY, GROSS AND MICROSCOPIC EXAMINATION			
0636	90714	TETANUS AND DIPHTHERIA TOXOIDS(Td)ADSORBED, PRESERVATIVE FREE			
	A4550	SURIGICAL TRAYS			
0250	J0330	INJECTION, SUCCINYLCHOLINE CHLORIDE, UP TO 20 MG			
0636	J0461	INJECTION, ATROPINE SULFATE, 0.01 MG			
0250	J0690	INJECTION, CEFAZOLIN SODIUM, 500 MG			
0250	J0696	INJECTION, CEFTRIAXONE SODIUM, PER 250 MG			
0636	J0744	INJECTION, CIPROFLOXACIN FOR INTRAVENOUS INFUSION, 200 MG			
0636	J0780	INJECTION, PROCHLORPERAZINE, UP TO 10 MG			
0636	J1094	INJECTION, DEXAMETHASONE ACETATE, 1 MG			
0250	J1100	INJECTION, DEXAMETHASONE SODIUM PHOSPHATE, 1 MG			
0636	J1170	INJECTION, HYDROMORPHONE, UP TO 4 MG			
0250	J1200	INJECTION, DIPHENHYDRAMINE HCL, UP TO 50 MG			
0636	J1580	INJECTION, GARAMYCIN, GENTAMICIN, UP TO 80 MG			
0636	J1626	INJECTION, GRANISETRON HYDROCHLORIDE, 100 MCG			



# These are the drugs and supplies to be covered with no member cost sharing when billed as outpatient transcervical sterilization

REV_CD	PROC_CD	HCPCS_CD _DS			
0636	J1644	INJECTION, HEPARIN SODIUM, PER 1000 UNITS			
0259	J1650	INJECTION, ENOXAPARIN SODIUM, 10 MG			
0250	J1790	INJECTION, DROPERIDOL, UP TO 5 MG			
0250	J1885	INJECTION, KETOROLAC TROMETHAMINE, PER 15 MG			
0636	J1956	INJECTION, LEVOFLOXACIN, 250 MG			
0259	J2001	INJECTION, LIDOCAINE HCL FOR INTRAVENOUS INFUSION, 10 MG			
0250	J2175	INJECTION, MEPERIDINE HYDROCHLORIDE, PER 100 MG			
0259	J2180	INJECTION, MEPERIDINE AND PROMETHAZINE HCL, UP TO 50 MG			
0250	J2250	INJECTION, MIDAZOLAM HYDROCHLORIDE, PER 1 MG			
0250	J2270	INJECTION, MORPHINE SULFATE, UP TO 10 MG			
0636	J2300	INJECTION, NALBUPHINE HYDROCHLORIDE, PER 10 MG			
0250	J2310	INJECTION, NALOXONE HYDROCHLORIDE, PER 1 MG			
0636	J2370	INJECTION, PHENYLEPHRINE HCL, UP TO 1 ML			
0259	J2405	INJECTION, ONDANSETRON HYDROCHLORIDE, PER 1 MG			
0250	J2550	INJECTION, PROMETHAZINE HCL, UP TO 50 MG			
0636	J2597	INJECTION, DESMOPRESSIN ACETATE, PER 1 MCG			
0250	J2710	INJECTION, NEOSTIGMINE METHYLSULFATE, UP TO 0.5 MG			
0250	J2765	INJECTION, METOCLOPRAMIDE HCL, UP TO 10 MG			
0636	J2780	INJECTION, RANITIDINE HYDROCHLORIDE, 25 MG			
0636	J2930	INJECTION, METHYLPREDNSILONE SODIUM SUCCINATE, UP TO 40 MG			
0250	J3010	INJECTION, FENTANYL CITRATE, 0.1 MG			
	J3360	INJECTION, DIAZEPAM, UP TO 5 MG			
0636	J3410	INJECTION, HYDROXYZINE HCL, UP TO 25 MG			
0250	J7030	INFUSION, NORMAL SALINE SOLUTION , 1000 CC			
0258	J7040	INFUSION, NORMAL SALINE SOLUTION, STERILE (500 ML=1 UNIT)			



# These are the drugs and supplies to be covered with no member cost sharing when billed as outpatient transcervical sterilization

REV_CD	PROC_CD	HCPCS_CD_DS			
0636	J7050	INFUSION, NORMAL SALINE SOLUTION , 250 CC			
0258	J7060	5% DEXTROSE/WATER (500 ML = 1 UNIT)			
0250	J7120	RINGERS LACTATE INFUSION, UP TO 1000 CC			
0250	J7613	ALBUTEROL, INHALATION SOLUTION, FDA APPROVED FINAL PRODUCT, NON- COMPOUNDED, ADMINSTERED THROUGH DME UNIT DOSE, 1 MG			
0250	S0020	INJECTION, BUPIVICAINE HYDROCHLORIDE, 30 ML			
0259	S0028	INJECTION, FAMOTIDINE, 20 MG			
0250	S0077	INJECTION, CLINDAMYCIN PHOSPHATE, 300 MG			
0250	J7120	RINGERS LACTATE INFUSION, UP TO 1000 CC			
0258	J7120	RINGERS LACTATE INFUSION, UP TO 1000 CC			
	J7302	LEVONORGESTREL-RELEASING INTRAUTERINE CONTRACEPTIVE SYSTEM, 52 MG			
	J7307	ETONOGESTREL (CONTRACEPTIVE) IMPLANT SYSTEM, INCLUDING IMPLANT A SUPPLIES			
0250	J7613	ALBUTEROL, INHALATION SOLUTION, FDA APPROVED FINAL PRODUCT, NON- COMPOUNDED, ADMINSTERED THROUGH DME UNIT DOSE, 1 MG			
0250	S0020	INJECTION, BUPIVICAINE HYDROCHLORIDE, 30 ML			
0259	S0020	INJECTION, BUPIVICAINE HYDROCHLORIDE, 30 ML			
0259	S0028	INJECTION, FAMOTIDINE, 20 MG			
0250	S0077	INJECTION, CLINDAMYCIN PHOSPHATE, 300 MG			



Drug Type	Drug specific	CPT/HCPCS or Therapeutic Class Code (check code va- lidity based on service date)	Date coverage begins	Note
ASPIRIN	None	Preventive Code A on Stand Alone drug inquiry	"06/01/2015 Coverage for low dose aspirin for preeclampsia. 10/01/2010 As associ- ated with Aspirin for the prevention of myocardial infarction and ischemic stroke"	
"BOWEL PREPARATION "	Minimum age 50 yrs	Preventive Code B on Stand Alone drug inquiry	11/1/2016	"Prime will administer age re- quirements. Paper and embed- ded BCBSKS claims will not. From FAQ 4/2016"
"BREAST CANCER PRIMARY PREVENTION "	Minimum age 35 yrs	Preventive Code T on Stand Alone drug inquiry		Prime will administer age require- ments. Paper and embedded BCBSKS claims will not.
FLUORIDE				
"Dental Products & Combina- tions "	"6 months - 16 yrs"	Preventive Code V on Stand Alone drug inquiry		Prime will administer age require- ments. Paper and embedded BCBSKS claims will not.
"Supplements & Combinations "	"6 months - 5 yrs"	Preventive Code V on Stand Alone drug inquiry		Prime will administer age require- ments. Paper and embedded BCBSKS claims will not.
"FOLIC ACID SUPPLEMENTS	None	Preventive Code V on Stand Alone drug inquiry	10/01/2010	Jan 2017 USPSTF reiterated recommendation; reiterated again in Aug 2023
"IRON SUPPLEMENTS "	0 to 12 months	Preventive Code V on Stand Alone drug inquiry	10/01/2010	Prime will administer age require- ments. Paper and embedded BCBSKS claims will not.



Drug Type	Drug specific	CPT/HCPCS or Therapeutic Class Code (check code va- lidity based on service date)	Date coverage begins	Note
"SINGLE AGENT STATINS	40-75 years	Preventive Code H on Stand Alone drug inquiry		Prime will administer age require- ments. Paper and embedded BCBSKS claims will not.
"TOBACCO CESSATION	None	Preventive Code S on Stand Alone drug inquiry	10/01/2010	
"VACCINES				
See Immunization Tab				
"CONTRACEPTIVES Barrier Method Types •Cervical Caps •Diaphragms •Female Condom •Spermicide •Sponge •Phexxi Gel Emergency Method Types •Emergency Ella •Emergency Progestin Hormonal Method Types •Injectable Progestin •Oral Combined •Oral Extended Continuous •Oral Progestin •Transdermal Combined •Vaginal Combined	None	Preventive Code C on Stand Alone drug inquiry (OTC)	08/01/2012	•Added Phexxi Gel effective 1/1/2023. scb



Drug Type	Drug specific	CPT/HCPCS or Therapeutic Class Code (check code va- lidity based on service date)	Date coverage begins	Note
"HIV PrEP (preexposure prophylaxis) "	None	Preventive Code PREP on stand-alone drug inquiry.	07/01/2020	•Preventive Medication Guide will be updated to reflect HIV PrEP on 01.01.2021. Ijn